February 11, 2019 - 10:20 PM EST
Aldeyra Looks To Add To Its Extensive Pipeline Treating Eye Diseases

Aldeyra Looks To Add To Its Extensive Pipeline Treating Eye Diseases

Aldeyra Therapeutics (ALDX) acquired a private biotech by the name of Helio Vision Incorporated. The reason for acquiring this biotech was so that it could add an additional phase 3-ready asset into its pipeline. Typically, a small-cap biotech won't acquire another company. However, I believe that this acquisition makes sense because it is complementary to the company's current business model of developing therapies for a variety of eye diseases. In addition, this acquisition was made in a position of strength, because the biotech has been able to achieve positive results in other mid-stage

Read more ...


Source: SeekingAlpha (February 11, 2019 - 10:20 PM EST)